Acadia Healthcare Company Inc vs Becton Dickinson and Co — how do they compare? Acadia Healthcare Company Inc trades at $31.18 (market cap $2.96B), while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co is far larger — about 16.5× Acadia Healthcare Company Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | BDX | |
|---|---|---|
Market Cap | $2.96B | $48.93B |
Sector | Health | Health |
52-Week High | $35.61 | $185.39 |
52-Week Low | $11.68 | $138.62 |
Enterprise Value | $5.35B | $65.03B |
Dividend Yield | — | 2.34% |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.53, up 2.64% today, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth with Q2 2026 earnings beating estimates, but faces profitability challenges with negative net income margins. Analyst consensus remains positive with 68% buy ratings and a $36 price target, though ongoing legal investigations create headwinds.
The outlook balances operational strength against financial risks. Revenue growth and facility expansion support upside potential, but negative profitability and legal uncertainties warrant caution. The stock offers 14% upside to consensus target if execution improves, but investors should monitor earnings sustainability and legal developments closely.
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →